Efficacy News and Research

RSS
Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

Autism Speaks funds high priority research for treatment of ASD

Autism Speaks funds high priority research for treatment of ASD

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Physician’s unfavorable attitudes about opioid drugs linked with lower rates of prescribing

Physician’s unfavorable attitudes about opioid drugs linked with lower rates of prescribing

Researchers develop breakthrough approach to reduce harmful effects from blood transfusions

Researchers develop breakthrough approach to reduce harmful effects from blood transfusions

New method of maturing human heart cells mimics fetal heart rate

New method of maturing human heart cells mimics fetal heart rate

IAIM seeks to support immunization managers to achieve vaccination goals

IAIM seeks to support immunization managers to achieve vaccination goals

European study to evaluate CardioFocus' HeartLight Endoscopic Ablation System in AF patients

European study to evaluate CardioFocus' HeartLight Endoscopic Ablation System in AF patients

Thermo Fisher Scientific and Newman-Lakka Institute collaborate to develop new diagnostic approaches for personalized cancer treatment

Thermo Fisher Scientific and Newman-Lakka Institute collaborate to develop new diagnostic approaches for personalized cancer treatment

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.